Hello, myeloma world.

We hope your week has gotten off to a great start.

We're looking forward to reviewing three new myeloma-related research studies with you today.

The first study we summarize in today's report focuses on the survival of older blood cancer patients, including (of course) older multiple myeloma patients.

The second study presents the results of the CHAMPION-1 clinical trial, which tested once weekly Kyprolis in com­bi­na­tion with dexa­meth­a­sone in re­lapsed multiple myeloma patients.

The final study we …

This month’s column has nothing to do with multiple myeloma the disease. There will be no discussion of M-spikes or light chains. I will not talk about treatments or side effects. I won’t offer details of my stem cell transplant and how I responded to it.

But this column has everything to do with what having myeloma has done to and for me as a person – a father, a grandfather, and a partner.

For the first 13 years of …

It's good to see you again, myeloma world.

We got tied up the past couple days with, among other things, coverage of the Empliciti approval in Europe. But we're glad to be back and we have two new research studies that we'd like to discuss with you.

First, we take a look at an Israeli study that does a deep dive into the t(11;14) chro­mosomal abnormality in newly diagnosed multiple myeloma patients. The focus of this particular deep dive …

The Euro­pean Com­mis­sion has approved Empliciti (elo­tuzu­mab) for the treat­ment of mul­ti­ple myeloma.

The ap­prov­al means that myeloma patients in Europe will now be able to be treated with Empliciti without having to en­roll in a clin­i­cal trial.

Empliciti's Euro­pean ap­prov­al comes on the heals of its ap­prov­al late last No­vem­ber in the United States, the mar­ket in which the drug re­ceived its first ever regu­la­tory ap­prov­al. As in the United States, Empliciti has been approved in Europe …

I just returned from a long trip to Europe, and boy do I feel refreshed! The reason I think I feel so good is that I took a holiday not just from work and the mundane problems of home, but I also took a holiday from my multiple myeloma.

I once again find myself feeling guilty for being one of the healthiest guys in the myeloma ward, so let me explain.

My wife and I spent about three weeks in …

How has your week started, myeloma world?

We hope it's going well so far.

We once again have a rather long list of new myeloma research we'd like to discuss with you. We sus­pect most of our readers will find at least one or two studies in the report to be of particular interest.

We begin today's report with a discussion of a somewhat rare eye-related side effect of Velcade (bor­tez­o­mib) and a possible way to control the …

As many of you may remember, I re-started treatment with Revlimid (lena­lido­mide) and dexa­metha­sone (Decadron) a year and a half ago because I relapsed.

Luckily, I’m responding well to the treatment. My M-spike has decreased to an almost undetectable level, and my light chains are in the normal range.

However, the treatment leaves me somewhat immuno­com­pro­mised, which means that I am at an increased risk of infection. I have noticed, for example, that I frequently pick up respiratory infections when …